

# Iuri Marinov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7193194/publications.pdf>

Version: 2024-02-01

37  
papers

663  
citations

516215

16  
h-index

580395

25  
g-index

37  
all docs

37  
docs citations

37  
times ranked

928  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCs in patients with paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 179-192.	0.7	7
2	Sensitive and accurate identification of PNH clones based on ICCS/ESCCA PNH Consensus Guidelinesâ€”A summary. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 73-81.	0.7	11
3	Immunophenotyping of Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Methods in Molecular Biology</i> , 2019, 2032, 323-354.	0.4	3
4	Highâ€”sensitivity 5â€”, 6â€”, and 7â€”color PNH WBC assays for both Canto II and Navios platforms. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 637-651.	0.7	23
5	Performance Characteristics of a Nonâ€”Fluorescent Aerolysinâ€”Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Assay for Simultaneous Evaluation of PNH Neutrophils and PNH Monocytes by Flow Cytometry, Following Published PNH Guidelines. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 257-263.	0.7	11
6	ICCS/ESCCA Consensus Guidelines to detect GPIâ€”deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 3 â€” Data Analysis, Reporting and Case Studies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 49-66.	0.7	55
7	ICCS/ESCCA Consensus Guidelines to detect GPIâ€”deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 2 â€” Reagent Selection and Assay Optimization for Highâ€”Sensitivity Testing. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 23-48.	0.7	50
8	Accurate and High Sensitivity Identification of PNH Clones by Flow Cytometry. , 2018, , .		0
9	Re Gatti etÂ”al (Eur J Haematol 2017 Mar 23. Doi: 10.1111/ejh.12885). <i>European Journal of Haematology</i> , 2018, 101, 804-806.	1.1	3
10	Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2016, 96, 276-284.	1.1	23
11	Interferon-Î± Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. <i>PLoS ONE</i> , 2016, 11, e0155959.	1.1	18
12	FY*Asilencing by the GATA-motif variantFY*A(â”69C)in a Caucasian family. <i>Transfusion</i> , 2015, 55, 2616-2619.	0.8	5
13	Intraâ€”and interlaboratory variability of paroxysmal nocturnal hemoglobinuria testing by flow cytometry following the 2012 Practical Guidelines for highâ€”sensitivity paroxysmal nocturnal hemoglobinuria testing. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 229-236.	0.7	24
14	Novel human multiple myeloma cell line UHKT-893. <i>Leukemia Research</i> , 2013, 37, 320-326.	0.4	2
15	Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2133-9.	1.4	5
16	Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. <i>Pediatric Nephrology</i> , 2012, 27, 73-81.	0.9	17
17	Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia MO without Erythroblastic and Megakaryocytic Dysplasia. <i>Acta Haematologica</i> , 2011, 126, 129-134.	0.7	5
18	Optimal pretreatment timing for high load dosing (600Â”mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. <i>International Journal of Cardiology</i> , 2010, 144, 255-257.	0.8	13

#	ARTICLE	IF	CITATIONS
19	PBPC collections: Management, techniques and risks. <i>Transfusion and Apheresis Science</i> , 2010, 43, 237-243.	0.5	17
20	Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2009, 9, 62-77.	0.2	20
21	Clopidogrel resistance "Live" $\frac{1}{2}$ the risk of stent thrombosis should be evaluated before procedures. <i>Thrombosis Journal</i> , 2009, 7, 6.	0.9	5
22	High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 257-262.	0.5	13
23	Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking "Paradox". <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 368-372.	0.8	25
24	Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL. <i>Transfusion and Apheresis Science</i> , 2007, 36, 149-158.	0.5	11
25	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. <i>Nutrition Research</i> , 2007, 27, 181-185.	1.3	1
26	UVA-activated 8-methoxypsoralen (PUVA) causes G2/M cell cycle arrest in Karpas 299 T-lymphoma cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2006, 85, 39-48.	1.7	20
27	Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells. <i>Journal of Applied Biomedicine</i> , 2006, 4, 95-104.	0.6	2
28	Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL-MK1 cells. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 268-280.	1.2	16
29	PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. <i>Transfusion and Apheresis Science</i> , 2005, 32, 167-176.	0.5	36
30	Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 32, 262-269.	0.6	24
31	Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2003, 69, 71-85.	1.7	99
32	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2003, 166, 197-198.	0.4	8
33	Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. <i>Vaccine</i> , 2003, 21, 1125-1136.	1.7	55
34	Monoclonal antibody to human chronic myeloid leukemia cell line MOLM-7 specifically reacts with an antigen of apoptotic cells. <i>Leukemia Research</i> , 2002, 26, 45-54.	0.4	1
35	The efficiency of PBPC collections and the relationship to the precollection concentration of CD 34+ cells in blood. <i>Transfusion Science</i> , 1999, 20, 181-188.	0.6	5
36	Three cases of near-tetraploid acute myeloid leukemias originating in pluripotent myeloid progenitors. <i>Leukemia Research</i> , 1998, 22, 581-588.	0.4	29

#	ARTICLE	IF	CITATIONS
37	Validation of a single tube 3-colour immature red blood cell screening assay for the detection and enumeration of small, medium and large paroxysmal nocturnal haemoglobinuria clones by flow cytometry. International Journal of Laboratory Hematology, 0, , .	0.7	1